Ország: Egyesült Királyság
Nyelv: angol
Forrás: myHealthbox
Mesalazine
Warner Chilcott UK Limited
A07EC02
Mesalazine
500mg
suppositories
rectal use
10 suppositories
POM - Prescription Only Medicine
Actavis Group PTC
Aminosalicylic acid and similar agents
For the treatment of mild to moderate acute exacerbations of ulcerative colitis. The suppositories are particularly appropriate in patients with distal disease. For the maintenance of remission of ulcerative colitis.
Authorised
2015-07-30
Asacol (Mesalazine) PIL Warner Chilcott UK item no: print proof no: origination date: originated by: revision date: revised by: dimensions: pharmacode: colours/plates: approved for print/date Non Printing Colours 1. 2. 3. 4. 5. 6. 1. 2. 3. date sent: supplier: approved: min pt size: TECHNICAL APPROVAL black AAAI0567 4 22.6.15 db 22.8.15 db Haupt Pharma Wulfingen GmbH 170 x 300 7.5 pt 22.6.15 22.6.15 * Please note that only Actavis Global Artwork Studios are permitted to make changes to the above artwork. No changes are permitted by any 3rd party other than added notes and mark ups for required changes. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Asacol Suppositories are and what they are used for 2. Before you use Asacol Suppositories 3. How to use Asacol Suppositories 4. Possible side effects 5. How to store Asacol Suppositories 6. Further information 1. WHAT ASACOL SUPPOSITORIES ARE AND WHAT THEY ARE USED FOR Asacol Suppositories contain the active substance mesalazine (also known as 5-aminosalicylic acid) which is an anti- inflammatory drug used in the treatment of ULCERATIVE COLITIS – a disease of the large bowel (colon) and back passage (rectum) in which the lining of the bowel becomes inflamed (red and swollen). Symptoms can include rectal bleeding, frequent diarrhoea and abdominal pain. The suppositories act locally in the rectum to reduce inflammation and can also prevent further episodes (flares) of ulcerative colitis. They are particularly useful when symptoms of ulcerative colitis affect the Olvassa el a teljes dokumentumot
Asacol 500mg Suppositories Summary of Product Characteristics Updated 14Sep2015 | Warner Chilcott UK Limited (a subsidiary of Actavis PLC) 1. Name of the medicinal product Asacol 500mg Suppositories 2. Qualitative and quantitative composition Asacol Suppositories contain 500mg mesalazine per suppository. 3. Pharmaceutical form Opaque, beige suppositories, containing 500mg mesalazine. 4. Clinical particulars 4.1 Therapeutic indications For the treatment of mild to moderate acute exacerbations of ulcerative colitis. The suppositories are particularly appropriate in patients with distal disease. For the maintenance of remission of ulcerative colitis. 4.2 Posology and method of administration _ADULTS:_ _Suppositories 250 mg:_ Three to six suppositories a day in divided doses, with the last dose at bedtime. _Suppositories 500 mg:_ A maximum of three suppositories a day in divided doses, with the last dose at bedtime. _ELDERLY: _The normal adult dosage may be used unless renal function is impaired (see section 4.4). _CHILDREN:_ There is no dosage recommendation. 4.3 Contraindications A history of sensitivity to salicylates or renal sensitivity to sulphasalazine. Confirmed severe renal impairment (GFR <20 ml/min). Children under 2 years of age. 4.4 Special warnings and precautions for use Use in the elderly should be cautious and subject to patients having normal renal function. Renal disorder: Mesalazine is excreted rapidly by the kidney, mainly as its metabolite, Nacetyl5aminosalicylic acid. In rats, large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Asacol should be used with extreme caution in patients with confirmed mild to moderate renal impairment (see section 4.3). Treatment with mesalazine should be discontinued if renal function deteriora Olvassa el a teljes dokumentumot